Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pharmaceutical Packaging: What You’re Doing Wrong


Pharmaceutical Packaging

Share this!

January 28, 2016 | by Sarah Massey, M.Sc.

While pharmaceutical manufacturers pay a great deal of attention to ensuring they’re compliant with good manufacturing practices (GMPs) and US Food and Drug Administration (FDA) regulations when manufacturing a drug, pharmaceutical packaging can often be an afterthought. Since it’s estimated that 50 percent of pharmaceutical recalls are due to errors in product labeling or packaging artwork, this is an area pharmaceutical manufacturers can’t afford to ignore. Take our quiz to find out where the errors are in your pharmaceutical packaging work flow!

Mislabeling, or poorly packaging a pharmaceutical product carries a number of dangers for the manufacturer and the end user, including:

  • Risks to patient safety – Patient trust in the accuracy of their prescription label is of the utmost importance. Errors in labeling could cause misuse of a drug leading to serious side effects.
  • Compliance issues with the FDA – The FDA has clear guidelines on pharmaceutical packaging which outline a number of items that must be present on the label. If a manufacturer fails to comply with the regulations, the FDA may issue a recall of a product.
  • Cost of recall and potential fines – The financial cost of recalling a product due to a labeling error can be substantial.
  • Damage to company’s public image and reputation – Product recalls of any kind are made very public and can have a significantly negative effect on the reputation of the pharmaceutical producer.
  • Time lost fixing issues – The time spent investigating the cause of a labeling error and the subsequent resolution of the issue could be better spent investing in new products.

Current FDA Regulations

The FDA has released draft guidance specifying the way manufacturers are required to label their pharmaceutical products. These regulations were put in place in order to protect the consumer and standardize the packaging industry. Some current FDA recommendations for package labeling include:

  • The most important product information should appear on the most visible display panel of the package.
  • Labels themselves should be readable to the consumer as well as easy to understand.
  • Container labels should be unique and avoid too many similarities with other product packages.
  • Product codes should also be different enough to distinguish between two pharmaceuticals.
  • Blister packs should include a number of pieces of information about the drug – including the nonproprietary name and the trade name, strength, expiration date, lot number, bar code, and manufacturer – on each individual blister cell so this is always visible to the patient.

Most Common Errors

In order to ensure compliance with FDA packaging regulations, it’s important to understand the most commonly made errors in pharmaceutical package labeling, and some reasons why they might occur.

  • Gross Errors – These occur when necessary information is missing from label artwork. This type of error most often occurs when regulatory requirements change but the manufacturer fails to change the package artwork in response to the new guidelines.
  • Context and Meaning Errors – These types of errors occur when information on the label artwork is presented in an unclear or ambiguous way. A context or meaning error could occur if incorrect punctuation is used on the label.
  • Content Errors – These occur when there are significant errors in the detailed content of the artwork. The error could be due to the incorrect usage of a symbol on the package label.
  • Technical Errors – These errors are in functional components of the artwork, including the product barcode.

Why Errors Occur

When it comes to pharmaceutical packaging and labeling, a small but problematic detail can lead to a significant error. Once errors have been identified and corrective actions have been made, it’s necessary to identify the source of the error in order to avoid similar issues in the future. Some reasons why errors occur during labeling include:

  • Inconsistencies in processes – If the processes in place governing the design of the artwork are inconsistent or conflicting, errors can easily occur.
  • Gaps in competence – If the operator performing the task of designing the labels are inadequately trained, there is an increased risk of error.
  • Too little quality time – If an operator is rushed or overworked, errors in labeling can be overlooked.
  • Errors in reference information – If the information being referred to when designing the label is incorrect, those errors will be transcribed onto the finished packaging design.
  • Human error – The number of people involved in the process of designing and eventually applying an artwork increases the risk of error.
  • Technology error – If the software used to design the label lacks built-in control tools for proofreading and correcting label designs, errors could be overlooked.

Changing Regulations

While current pharmaceutical labels require product lot number and expiration date, industry insiders believe the FDA will soon require manufacturers to add more unique codes to their packages, in order to increase control over the supply chain. In order to meet changes in labeling regulation, some manufacturers have begun integrating a dedicated labeling system designed to meet GMP standards and stop errors in labeling before they become a systemic issue.

To learn more about pharmaceutical packaging management and how you can take control of your packaging supply chain, register for the webinars in the banner below! What do you think are the biggest mistakes pharmaceutical companies make when it comes to packaging? Share your opinion in the comments section below!



Gain Control of Your Pharmaceutical Packaging Supply Chain

Minimize the Risk of Recalls - The Cost of Poor Pharmaceutical Packaging Management

Keywords: Pharmaceutical Packaging, FDA, GMP



Share this with your colleagues!

3 Reasons Why Pharma Marketers Are Failing At Social Media

January 20, 2016 - Pharma marketers have historically been much more comfortable with the one-sided conversation of a direct-to-consumer (DTC) ad, but as the industry moves more and more towards patient-centricity, it is becoming necessary for drugmakers to increase engagement with their stakeholders.

Martin Shkreli: A Timeline Of Events That Shook Up The Pharmaceutical Industry

January 13, 2016 - While being taken into custody has nothing to do with his pricing decisions as CEO of Turing, the years leading up to the controversy surrounding Daraprim reveals detail about Shkreli’s entry into the pharmaceutical sector, and his contribution to the reputation of greed often conferred upon the pharma industry.

Top 5 Pharmaceutical Industry News Stories of 2015

December 15, 2015 - As the 2015 calendar year draws to a close, the Xtalks Blog thought it would be a good idea to explore the top 5 pharmaceutical industry topics of the year, and make predictions on what people in the industry can expect for 2016.

Top 2 FDA Issues Affecting Compounding Pharmacies and Outsourcing Facilities

December 3, 2015 - While the FDA has issued guidance on what types of compounding facilities should register under section 503B, many compounding pharmacies are unsure of whether their organization is eligible for exemptions and if those benefits would outweigh the FDA scrutiny. Still other compounders have registered with the agency, but are struggling to comply with stricter regulations.

Transparency in Clinical Trials: Why The Industry Isn’t Measuring Up

November 25, 2015 - A recent study conducted by Bioethics International – a not-for-profit organization that keeps tabs on the way pharmaceutical companies develop and market drugs in order to determine the ethics behind these practices – found that many large pharmaceutical companies failed to achieve transparency in their clinical trial results.

Is Your Clinical Trial Ready For An FDA Inspection? Surprising Insights Gained From An Interview With An Inspection Trainer

November 17, 2015 - I spoke with Janet E. Holwell, CCRA, CCRA, TIACR clinical research consultant, to understand why many clinical trial professionals dread FDA inspections, and how they can be better prepared to deal with one and its potential aftermath.

The FDA Food Safety Modernization Act: Is Your Organization Ready For Compliance?

November 5, 2015 - Since January 2013, the Food and Drug Administration (FDA) has been working towards implementing new rules on food safety, as part of the agency’s Food Safety Modernization Act (FSMA).

Virtual Clinical Trials – Can Remote Trials Change The Clinical Trial Landscape?

October 29, 2015 - Virtual clinical trials are a relatively new method of collecting safety and efficacy data from human trial participants.

Drug Prices: To Cap or Not To Cap?

October 20, 2015 - Recent price hikes on some new drugs – along with those that were approved by the FDA decades ago – have some asking the question, are these costs justified?

Russia & Ukraine Cut Import Taxes, Red Tape for Clinical Trial Supplies

October 13, 2015 - Clinical trial professionals are applauding changes in regulations that make it easier and less expensive to conduct global clinical trials in Russia and Ukraine – two countries whose requirements had been provoking frustration and concern.

Transactional Outsourcing and Strategic Partnerships: An Insider’s Perspective

October 1, 2015 - To understand the benefits – and the common challenges – associated with strategic partnerships, I spoke with Richard Fazackerley, Technical Director, Aesica Pharmaceuticals, who will be speaking in more detail about strategic partnerships in a webinar on October 5th.

Insights Into The Emerging Health Monitoring Medical Device Market

September 24, 2015 - To get an insider’s perspective on where the health monitoring medical device industry is heading, and how these devices could improve outcomes for clinical trials, I spoke with Deepak Prakash, Global Director of Marketing, Digital Health, for Vancive Medical Technologies.

Precision Medicine and the Paradigm Shift In The Development of Novel Cancer Therapies

September 17, 2015 - To further understand how the paradigm shift in cancer research, diagnosis and treatment will affect how drugs are developed and clinical trials are conducted in Canada, I spoke to Dr. Sian Bevan, director of research for the Canadian Cancer Society.

Medical Device Innovation: Blurring the Lines Between Medical Necessity and Personal Accessory

September 9, 2015 - As sales of wearable medical monitors rise, and healthy, average consumers increasingly look for high-tech gadgets to monitor their health, device manufacturers are developing technology which can be marketed to both healthy individuals as well as those with specific medical conditions.

Recent Medical Applications of 3-D Printing and the Future of Medical Device Manufacture

September 2, 2015 - While the use of 3-D printers in the pharmaceutical industry is still in its infancy, three-dimensional printing technology has been used for other applications such as medical device manufacture and improvements in research tools available for drug testing.

Printing Your Prescription: How 3-D Printing Technology is Affecting the Pharmaceutical Industry

August 26, 2015 - In the wake of the FDA’s first approved 3-D printed drug – which happened earlier this year – and the promise of three others in the works, experts are predicting that the future of the pharmaceutical industry lies in the development of printable drug products.

Are There Adequate Alternatives to Animal Testing?

August 19, 2015 - Three promising in vitro and in silico technologies including, Modular Immune in vitro Construct (MIMIC), Organ-on-a-Chip and Computer Models of Adverse Drug Reactions, which could reduce the need for animals in research, are reviewed in more detail.


Copyright © 2016-2017 Honeycomb Worldwide Inc.